349 related articles for article (PubMed ID: 28762060)
1. A 2-year observational study on treatment targets in psoriatic arthritis patients treated with TNF inhibitors.
Chimenti MS; Triggianese P; Conigliaro P; Tonelli M; Gigliucci G; Novelli L; Teoli M; Perricone R
Clin Rheumatol; 2017 Oct; 36(10):2253-2260. PubMed ID: 28762060
[TBL] [Abstract][Full Text] [Related]
2. Assessment of Response to Treatment, Remission, and Minimal Disease Activity in Axial Psoriatic Arthritis Treated with Tumor Necrosis Factor Inhibitors.
Lubrano E; Parsons WJ; Perrotta FM
J Rheumatol; 2016 May; 43(5):918-23. PubMed ID: 26980581
[TBL] [Abstract][Full Text] [Related]
3. Minimal Disease Activity and Remission in Psoriatic Arthritis Patients Treated with Anti-TNF-α Drugs.
Perrotta FM; Marchesoni A; Lubrano E
J Rheumatol; 2016 Feb; 43(2):350-5. PubMed ID: 26669925
[TBL] [Abstract][Full Text] [Related]
4. Need for Improvement in Current Treatment of Psoriatic Arthritis: Study of an Outpatient Clinic Population.
Michelsen B; Diamantopoulos AP; Høiberg HK; Soldal DM; Kavanaugh A; Haugeberg G
J Rheumatol; 2017 Apr; 44(4):431-436. PubMed ID: 28148701
[TBL] [Abstract][Full Text] [Related]
5. Subcutaneous anti-TNF alfa induced sustained minimal disease activity and remission in psoriatic arthritis patients: a retrospective study.
Perrotta FM; Lubrano E
Postgrad Med; 2016 Sep; 128(7):693-6. PubMed ID: 27494077
[TBL] [Abstract][Full Text] [Related]
6. Comparison of Composite Indices Tailored for Psoriatic Arthritis Treated with csDMARD and bDMARD: A Cross-sectional Analysis of a Longitudinal Cohort.
Lubrano E; De Socio A; Perrotta FM
J Rheumatol; 2017 Aug; 44(8):1159-1164. PubMed ID: 28572467
[TBL] [Abstract][Full Text] [Related]
7. Burden of Psoriatic Arthritis According to Different Definitions of Disease Activity: Comparing Minimal Disease Activity and the Disease Activity Index for Psoriatic Arthritis.
Wervers K; Vis M; Tchetveriko I; Gerards AH; Kok MR; Appels CWY; van der Graaff WL; van Groenendael JHLM; Korswagen LA; Veris-van Dieren JJ; Hazes JMW; Luime JJ
Arthritis Care Res (Hoboken); 2018 Dec; 70(12):1764-1770. PubMed ID: 29609220
[TBL] [Abstract][Full Text] [Related]
8. DAPSA, DAS28 and MDA predict long-term treatment regime in psoriatic arthritis. The Swedish Early Psoriatic Arthritis Cohort.
Lindqvist U; Wernroth ML; Husmark T; Larsson P; Geijer M; Teleman A; Theander E; Alenius GM
Clin Exp Rheumatol; 2017; 35(6):936-942. PubMed ID: 28628468
[TBL] [Abstract][Full Text] [Related]
9. Comparison of Composite Measure Remission Targets in Psoriatic Arthritis.
Farkas F; Ikumi N; Elmamoun M; Szentpetery A; FitzGerald O
J Rheumatol; 2021 Aug; 48(8):1272-1278. PubMed ID: 33722944
[TBL] [Abstract][Full Text] [Related]
10. Early psoriatic arthritis: short symptom duration, male gender and preserved physical functioning at presentation predict favourable outcome at 5-year follow-up. Results from the Swedish Early Psoriatic Arthritis Register (SwePsA).
Theander E; Husmark T; Alenius GM; Larsson PT; Teleman A; Geijer M; Lindqvist UR
Ann Rheum Dis; 2014 Feb; 73(2):407-13. PubMed ID: 23355078
[TBL] [Abstract][Full Text] [Related]
11. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
12. Effectiveness and safety of ustekinumab in naïve or TNF-inhibitors failure psoriatic arthritis patients: a 24-month prospective multicentric study.
Chimenti MS; Ortolan A; Lorenzin M; Triggianese P; Talamonti M; Costa L; Caso F; Favero M; Teoli M; Galluzzo M; Scarpa R; Punzi L; Perricone R; Ramonda R
Clin Rheumatol; 2018 Feb; 37(2):397-405. PubMed ID: 29302829
[TBL] [Abstract][Full Text] [Related]
13. Comparison of disease activity index for psoriatic arthritis (DAPSA) and minimal disease activity (MDA) targets for patients with psoriatic arthritis: A post hoc analysis of data from phase 3 tofacitinib studies.
Schneeberger EE; Citera G; Nash P; Smolen JS; Mease PJ; Soriano ER; Helling C; Szumski AE; Mundayat R; de León DP
Semin Arthritis Rheum; 2023 Feb; 58():152134. PubMed ID: 36476498
[TBL] [Abstract][Full Text] [Related]
14. Calprotectin strongly and independently predicts relapse in rheumatoid arthritis and polyarticular psoriatic arthritis patients treated with tumor necrosis factor inhibitors: a 1-year prospective cohort study.
Inciarte-Mundo J; Ramirez J; Hernández MV; Ruiz-Esquide V; Cuervo A; Cabrera-Villalba SR; Pascal M; Yagüe J; Cañete JD; Sanmarti R
Arthritis Res Ther; 2018 Dec; 20(1):275. PubMed ID: 30545393
[TBL] [Abstract][Full Text] [Related]
15. Discordance between tender and swollen joint count as well as patient's and evaluator's global assessment may reduce likelihood of remission in patients with rheumatoid arthritis and psoriatic arthritis: data from the prospective multicentre NOR-DMARD study.
Michelsen B; Kristianslund EK; Hammer HB; Fagerli KM; Lie E; Wierød A; Kalstad S; Rødevand E; Krøll F; Haugeberg G; Kvien TK
Ann Rheum Dis; 2017 Apr; 76(4):708-711. PubMed ID: 27707730
[TBL] [Abstract][Full Text] [Related]
16. Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease.
Helliwell P; Coates LC; FitzGerald O; Nash P; Soriano ER; Elaine Husni M; Hsu MA; Kanik KS; Hendrikx T; Wu J; Kudlacz E
Arthritis Res Ther; 2018 Oct; 20(1):242. PubMed ID: 30373651
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis: improvement in outcomes but persistent sex difference - 5-year follow-up study of a Norwegian outpatient clinic population.
Łosińska K; Michelsen B; Kavanaugh A; Korkosz M; Haugeberg G
Scand J Rheumatol; 2024 Jan; 53(1):10-20. PubMed ID: 37656147
[TBL] [Abstract][Full Text] [Related]
18. Disease activity in psoriatic arthritis (PsA): defining remission and treatment success using the DAPSA score.
Schoels MM; Aletaha D; Alasti F; Smolen JS
Ann Rheum Dis; 2016 May; 75(5):811-8. PubMed ID: 26269398
[TBL] [Abstract][Full Text] [Related]
19. Residual symptoms and disease burden among patients with psoriatic arthritis: is a new disease activity index required?
Kilic G; Kilic E; Nas K; Kamanlı A; Tekeoglu İ
Rheumatol Int; 2019 Jan; 39(1):73-81. PubMed ID: 30426235
[TBL] [Abstract][Full Text] [Related]
20. Comparison of Different Remission and Low Disease Definitions in Psoriatic Arthritis and Evaluation of Their Prognostic Value.
Coates LC; Gottlieb AB; Merola JF; Boone C; Szumski A; Chhabra A
J Rheumatol; 2019 Feb; 46(2):160-165. PubMed ID: 30323006
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
